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Background. Polymorphisms of renin-angiotensin system
(RAS) genes in patients with end-stage renal disease (ESRD)
on chronic hemodialysis may be associated with QTc inter-
val prolongation, leading to fatal arrhythmias. The objective
of this study was to determine (1) the prevalence of QTc pro-
longation in hemodialysis patients, and (2) the association of
a prolonged QTc in these patients with RAS polymorphisms
[angiotensin-converting enzyme-insertion/deletion (ACE-I/D),
angiotensin type 1 receptor-A1166C (AT1R-A1166C), and
angiotensinogen-M235T (AGT-M235T)].
Methods. Twelve-lead electrocardiograms (ECGs), serum
electrolytes (sodium, potassium, and calcium), and ACE and an-
giotensin II levels were obtained 10 to 12 hours after a hemodial-
ysis session in 43 patients with ESRD on chronic hemodialysis
[mean age (±SD), 55 ± 14 years]. Using polymerase chain re-
action (PCR), the presence of polymorphisms of the ACE-I/D,
AT1R-A1166C, and AGT-M235T genes was determined from
the buccal cells. A maximum QT interval in patients with sinus
rhythm and normal QRS duration was corrected for heart rate
using Hodges’ formula.
Results. Fifty-eight percent of the patients had QTc interval
prolongation (>440 msec). The ACE-DD genotype (P = 0.002)
and the C allele of the AT1R-A1166C gene (P = 0.004), but not
the AGT-M235T gene, contributed to QTc prolongation.
Conclusion. Polymorphisms of ACE and AT1R genes addi-
tively contribute to QTc prolongation found in a great majority
of ESRD patients. Therefore, ESRD patients with both or one
of these polymorphisms may be at a higher risk for sudden car-
diac death.
QT interval prolongation on the 12-lead electrocardio-
gram (ECG) is a predictor of sudden cardiac death due
to ventricular arrhythmias, which may account for 1.4%
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to 25% of deaths in end-stage renal disease (ESRD)
[1]. Numerous factors unique to ESRD and chronic
hemodialysis, including the increase in renin-angiotensin
system (RAS) activity, can remodel the cardiac ion chan-
nels, resulting in prolongation of ventricular repolar-
ization [2–4]. The latter manifests as a prolonged QT
interval. Superimposed genetic factors such as poly-
morphisms of RAS genes, which intensify the RAS
activity, may also contribute to the QT prolongation.
Specifically, the D allele of the angiotensin-converting
enzyme (ACE) insertion/deletion (I/D) polymorphism is
associated with QT-related ECG abnormalities in my-
ocardial infarction [5] and with ventricular fibrillation
[6]. Therefore, ACE-DD genotype and other RAS poly-
morphisms, angiotensin type 1 receptor-A1166C (AT1R-
A1166C) and angiotensinogen-M235T (AGT-M235T),
and within-RAS gene-gene interactions, may contribute
to QT prolongation in ESRD patients [7–10].
A hemodialysis session in ESRD patients may cause
QT prolongation [2–4], but it is not known whether the
QT interval remains prolonged several hours after the
session, and whether the RAS polymorphisms contribute
to the QT prolongation. The present study determined (1)
the prevalence of QT prolongation in patients on mainte-
nance hemodialysis, and (2) the effect of RAS polymor-
phisms on QT prolongation in these patients.
METHODS
Twelve-lead ECGs, serum electrolytes (sodium, potas-
sium, and calcium), and ACE and angiotensin II levels
were obtained 10 to 12 hours after a hemodialysis ses-
sion in 43 patients with ESRD on chronic hemodialysis
[mean age (±SD), 55 ± 14 years], who gave consent to
participate.
We determined the duration of the QT interval and the
presence of left ventricular hypertrophy. Two observers
blinded to the genetic data independently measured the
QT interval. The QT interval was measured in every lead
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Table 1. Mean QTc values for demographic and clinical variables
QTc
Variable Number Mean (SE) P value
Gender
Female 25 446.3 (5.4) 0.56
Male 18 451.3 (6.6)
Race/ethnicity
African American 3 472.0 (27.1) 0.34
Hispanic 25 449.2 (5.7)
Native American 5 436.2 (10.2)
Non-hispanic White 10 445.2 (5.8)
Hypertension
No 4 446.4 (4.2) 0.88
Yes 39 448.6 (4.6)
Antihypertensive therapy
No 7 443.3 (7.7) 0.60
Yes 36 449.4 (4.8)
History of diabetes
No 14 456.2 (8.2) 0.20
Yes 29 444.6 (4.7)
Coronary artery disease
No 31 448.7 (5.1) 0.90
Yes 12 447.5 (7.5)
Clinical congestive heart failure
No 35 449.5 (4.7) 0.59
Yes 8 443.7 (9.8)
from the onset of the QRS complex to the end of the T
wave. The end of the T wave was defined as a point where
the descending part of the T wave terminated on the iso-
electric baseline [11–13]. In the presence of U waves, the
end of the T wave was taken as the nadir between the T
and U waves. At the end of all measurements, the begin-
ning of the QRS and the end of the T wave were reexam-
ined by both observers, and discrepancies were resolved
before reporting the final measurement. The mean ab-
solute difference between the two readings was 5 msec.
Therefore, the relative interobserver error is 1%. When
the end of the T wave was not clear, the QRS complexes
were excluded from analysis. We also excluded patients
with a bundle-branch block, atrial fibrillation, or any ar-
rhythmia causing RR variation, and patients taking class I
or class III antiarrhythmic drugs. The presence of left ven-
tricular hypertrophy was determined using the Romhilt-
Estes point score system [13]. Table 1 summarizes the
demographic data and clinical variables.
Using polymerase chain reaction, the presence of poly-
morphisms of the ACE-I/D [14], AT1R-A1166C [8], and
AGT-M235T genes [15] were determined from the buc-
cal cells [16]. The study was approved by the Human
Research Review Committee of the University of New
Mexico Health Sciences Center.
A maximum QT interval in patients with sinus rhythm
and normal QRS duration was corrected for heart rate
using Hodges’ formula QTc = QT + 1.75 (heart rate –
60) [11, 12]. A prolonged QTc interval was defined as
>440 msec.
Table 2. Mean QTc values for angiotensin-converting enzyme (ACE)
and angiotensin type 1 receptor-A1166C (AT1R-A1166C)
polymorphisms
AT1R-A1166C genotype
ACE genotype AA AC or CC Total
DI or II 423.5 (3.5) 452.1 (5.4) 441.9 (4.5)
DD 456.1 (10.2) 469.4 (11.7) 460.5 (7.8)
Total 439.8 (6.4) 455.8 (5.0) 448.4 (4.2)
Data are mean (SEM). The gene-gene interaction P value = 0.35. The main
effects model shows P = 0.002 for the ACE genotype and P = 0.004 for the
AT1R-A1166C genotype.
Statistical analysis
One-way analyses of variance (ANOVA) were used to
test differences among mean QTc values for categoric de-
mographic and clinical variables, and genotypes for each
gene, and two-way ANOVA was used to test gene-gene
interaction. Pearson correlations were calculated for the
association between QTc values and continuous vari-
ables. The v 2 goodness-of-fit test was used to test whether
genotype distributions were significantly different from
the Hardy-Weinberg equilibrium. Step-wise regression
was used to develop a multivariate model with QTc as
the dependent variable. All calculations were done using
SAS, version 8.2.
RESULTS
The mean QT interval (msec) was 421 ± 34 (SD), and
the mean QTc interval was 448 ± 27 (SD). The QT in-
terval was not significantly associated with clinical vari-
ables or genotypes. The mean heart rate was 76 ± 10
(SD) per minute and was significantly negatively associ-
ated with age. Twenty-five of the 43 patients (58%) had a
prolonged QTc interval, >440 msec, and two (5%) had a
QTc >500 msec. The mean QTc was 464 msec in patients
with left ventricular hypertrophy by Romhilt-Estes crite-
ria [13] and 443 msec in patients without left ventricular
hypertrophy (P = 0.02). We found a positive association
between QTc and diastolic blood pressure (r = 0.30, P =
0.048), but the QTc duration was not significantly associ-
ated with the demographics and clinical variables shown
in Table 1. The electrolytes, ACE and angiotensin II levels
were not significantly abnormal.
The prevalences of the genotype were (1) ACE-DD,
15 (35%); ACE-I/D, 13 (30%); and ACE-II, 15 (35%);
(2) AT1R-CC, 7 (16%); AT1R-AC, 16 (37%); and AT1R-
AA, 20 (47%); and (3) AGT-TT, 13 (30%), AGT-MT,
21 (49%); and AGT-MM, 9 (21%). The distributions for
the AT1R and AGT genes were not significantly differ-
ent from the Hardy-Weinberg equilibrium (P = 0.49 for
AT1R-A1166C and P = 0.995 for AGT-M235T). The dis-
tribution for the ACE gene was significantly different
from the Hardy-Weinberg equilibrium (P = 0.03). Table 2
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shows mean QTc values for ACE and AT1R genotypes,
indicating additive effects of the ACE-DD genotype and
the C allele of the AT1R gene.
Independent variables contributing to QTc abnormality
Based on the results of the univariate analyses, we con-
structed a multivariate model using QTc as the depen-
dent variable and evaluated the following independent
variables which had univariate P value ≤ 0.20: body mass
index (BMI), systolic blood pressure, diastolic blood pres-
sure, the presence of left ventricular hypertrophy, history
of diabetes mellitus, presence of the DD genotype of the
ACE gene, and the presence of the C allele of the AT1R
genotype. We used step-wise linear regression to select
the parsimonious model which included the DD geno-
type of the ACE gene and the C allele of the AT1R gene.
The overall P value for the two independent variables
combined was 0.002 and the R2 value was 0.28. These
data suggest that the two genetic variables account for
28% of the variability in QTc values. The model coeffi-
cients estimate that the mean QTc increases by 26 msec
when the ACE-DD gene is present (P = 0.002) and in-
creases by 23 msec when the AT1R-C allele is present
(P = 0.004).
DISCUSSION
The QT interval on the surface ECG is an indirect
measure of ventricular repolarization. Studies relating to
congenital long QT syndrome have shown us that alter-
ations in cardiac ion channel function that lead to QT
prolongation may occur in several clinical conditions. The
QT prolongation may be associated with left ventricular
hypertrophy, hypertension, congestive heart failure, is-
chemic heart disease, diabetes mellitus, and ESRD; with
certain cardiac and noncardiac drugs; and with electrolyte
disturbances and acid base imbalance [17].
It is generally accepted that a hemodialysis session in-
duces prolongation of QT interval parameters (maximum
QTc duration and/dispersion) [18–26]. However, the ef-
fect of hemodialysis on QTc interval has been shown to
vary among studies [18–26]. In four studies, it increased
[18–21], and in five studies [22–26], it decreased or did not
change. The variations in QTc between the studies may
be due to methods of QT measurement, hemodialysis
technique, and severity of cardiac disease and associated
comorbid conditions.
Our study found prolonged baseline QTc interval in
58% of the patients 10–12 hours after a hemodialysis
session and with normal serum electrolytes. The QTc
duration was not significantly associated with the demo-
graphics, but it was longer in patients with left ventricular
hypertrophy. We found independent associations of the
ACE-DD genotype and AT1R-C allele with QTc pro-
longation, suggesting that genetic factors can affect QTc
interval in ESRD.
The RAS polymorphisms, particularly the ACE-DD
genotype and ATIR-C allele, have been shown to inten-
sify left ventricular hypertrophy, myocardial fibrosis, and
also hypertension [8, 9, 14, 15]. This contributes to elec-
trophysiologic remodeling of the myocardium, resulting
in prolongation of ventricular repolarization [4, 13, 17,
27]. Studies have shown QTc interval abnormalities in hy-
pertensive and postmyocardial infarction patients to be
greater in those homozygous for the D allele than in those
with the I/D or II genotype [5, 27]. Cardiac myocytes from
experimental models of renal failure have shown alter-
ations in (repolarizing) K+ channels, due to the direct
effects of uremia [4]. The repolarizing K+ channels are
also abnormal in conditions associated with ESRD, such
as hypertension [27, 28], diabetes mellitus [29], anemia
[4], chronic inflammation [30], and electrolyte abnormal-
ities and acidosis [18–26]. Cardiac ion channels can be
affected by such factors as the stretch of the myocytes
by high blood pressure [27, 31] and the paracrine fac-
tors released from the nonmyocyte cells [32] related to
the excessive intermyocyte collagen and fibrosis in car-
diac hypertrophy [28, 31] and uremia [4]. The changes
in ion channels are accompanied by the reexpression of
the fetal gene program [31]. Therefore, the QTc interval
prolongation found in over half of our patients may be
a marker of cardiac adaptation to numerous abnormal-
ities unique to the ESRD and chronic hemodialysis. It
is possible that the RAS overactivity associated with the
ACE-DD genotype intensifies the alterations in cardiac
ion channels, resulting in a longer QT interval. The asso-
ciation of ACE-DD genotype and AT1R-C allele with a
prolonged QTc interval in our study may be due to the
excessive cardiac tissue levels of angiotensin II [33, 34].
The angiotensin II modulates ventricular repolarization
by a direct effect on the ion channels of the ventricular
myocyte [17, 27–29, 31–35].
The lack of an association of the prolonged QTc with
the demographics and clinical variables, or with AGT
genotypes or within RAS gene-gene interactions may
be attributed to the small sample size and inadequate
variation in clinical findings. Furthermore, ACE and an-
giotensin II serum levels were not high, possibly due to
long-term therapy with ACE inhibitors and hemodialysis-
related hemodynamic changes.
CONCLUSION
QTc prolongation in ESRD patients on chronic
hemodialysis is a component of “ESRD cardiac pheno-
type” and may be a risk for fatal arrhythmias. Polymor-
phisms of ACE and AT1R genes additively contribute to
QTc prolongation found in a great majority of ESRD
patients. Therefore, ESRD patients with both or one of
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these polymorphisms may be at a higher risk for sudden
cardiac death.
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